EP1242088A1 — Oral mucosal dosage forms of apomorphine

USPTO Abstract

A pharmaceutical formulation for the prolonged-release oral mucosal administration of apomorpine which comprises a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt or pro-drug thereof in combination with a carrier comprising from about 10 percent by weight to about 95 percent by weight dextran, based upon the total weight of the formulation. In one embodiment of the invention, dextran having a molecular weight in the range between about 5000 Daltons and 100,000 Daltons is the sole component of the formulation for prolonging the release of the active drug component. In an alternative embodiment, a mixture of microcrystalline cellulose and dextran act as the components to prolong the release of apomorphine.